-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
89bio, Inc. (NASDAQ:ETNB) CFO Sells $74,396.97 in Stock
89bio, Inc. (NASDAQ:ETNB) CFO Sells $74,396.97 in Stock
89bio, Inc. (NASDAQ:ETNB – Get Rating) CFO Ryan Martins sold 5,947 shares of 89bio stock in a transaction that occurred on Tuesday, January 3rd. The shares were sold at an average price of $12.51, for a total transaction of $74,396.97. Following the transaction, the chief financial officer now directly owns 36,368 shares in the company, valued at approximately $454,963.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
89bio Price Performance
ETNB stock opened at $11.54 on Friday. 89bio, Inc. has a one year low of $2.00 and a one year high of $13.46. The company's fifty day moving average price is $9.69 and its 200-day moving average price is $6.71. The company has a debt-to-equity ratio of 0.08, a quick ratio of 5.81 and a current ratio of 5.81. The company has a market capitalization of $537.07 million, a PE ratio of -2.65 and a beta of 0.89.
Get 89bio alerts:Institutional Investors Weigh In On 89bio
Several large investors have recently bought and sold shares of ETNB. Rubric Capital Management LP bought a new stake in 89bio in the third quarter worth $5,729,000. Vanguard Group Inc. increased its position in 89bio by 69.1% in the third quarter. Vanguard Group Inc. now owns 1,671,584 shares of the company's stock worth $9,678,000 after purchasing an additional 683,232 shares during the last quarter. Deerfield Management Company L.P. Series C bought a new stake in 89bio in the second quarter worth $1,630,000. DAFNA Capital Management LLC increased its position in 89bio by 136.6% in the second quarter. DAFNA Capital Management LLC now owns 766,774 shares of the company's stock worth $2,469,000 after purchasing an additional 442,721 shares during the last quarter. Finally, Orchard Capital Management LLC increased its position in 89bio by 227.5% in the third quarter. Orchard Capital Management LLC now owns 551,879 shares of the company's stock worth $3,195,000 after purchasing an additional 383,386 shares during the last quarter. Institutional investors own 87.78% of the company's stock.
Analyst Ratings Changes
Several equities analysts have weighed in on the stock. Royal Bank of Canada lowered their price target on shares of 89bio from $35.00 to $29.00 and set an "outperform" rating on the stock in a report on Friday, November 11th. Raymond James lifted their price target on shares of 89bio from $14.00 to $25.00 and gave the company a "strong-buy" rating in a report on Wednesday, September 14th. Finally, Cantor Fitzgerald reissued an "overweight" rating and issued a $34.00 target price (up previously from $27.00) on shares of 89bio in a report on Monday, November 14th. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $25.25.About 89bio
(Get Rating)
89bio, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis.
See Also
- Get a free copy of the StockNews.com research report on 89bio (ETNB)
- MarketBeat: Week in Review 01/02-01/06
- Why is the CrowdStrike Stock Price Struggling?
- Four Undervalued Healthcare Stocks for 2023
- WWE Stock: Vince McMahon Wants Back In The Show
- NVIDIA Is Bottoming But Don't Buy It Just Yet
Receive News & Ratings for 89bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 89bio and related companies with MarketBeat.com's FREE daily email newsletter.
纳斯达克首席财务官瑞安·马丁斯在1月3日(星期二)的交易中出售了5,947股89生物公司的股票。这些股票以12.51美元的平均价格出售，总成交金额为74,396.97美元。交易完成后，首席财务官现在直接持有该公司36,368股股票，价值约454,963.68美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的，该文件可通过这个环节。
89Bio性价比
ETNB股票上周五开盘报11.54美元。89io，Inc.的一年低点为2.00美元，一年高位为13.46美元。该公司的50日移动均线价格为9.69美元，200日移动均线价格为6.71美元。该公司的负债权益比率为0.08，速动比率为5.81，流动比率为5.81。该公司市值为5.3707亿美元，市盈率为-2.65，贝塔系数为0.89。
到达89Bio警报：机构投资者参与89Bio
几家大型投资者最近买卖了ETNB的股票。Rubric Capital Management LP在第三季度购买了89Bio5,729,000美元的新股份。先锋集团(Vanguard Group Inc.)在第三季度将其在89Bio的头寸增加了69.1%。先锋集团目前持有1,671,584股该公司股票，价值9,678,000美元，上一季度又购买了683,232股。Deerfield Management Company L.P.C系列在第二季度购买了89Bio1,630,000美元的新股份。达夫纳资本管理有限责任公司在第二季度增持89Bio的头寸136.6。Dafna Capital Management LLC在上个季度额外购买了442,721股后，现在拥有766,774股该公司股票，价值2,469,000美元。最后，Orchard Capital Management LLC在第三季度将其在89Bio的持仓增加了227.5。Orchard Capital Management LLC现在拥有该公司551,879股股票，价值3,195,000美元，上个季度又购买了383,386股。机构投资者持有该公司87.78%的股票。
分析师评级发生变化
几位股票分析师对该股进行了加码。在11月11日周五的一份报告中，加拿大皇家银行将89Bio的目标价从35.00美元下调至29.00美元，并对该股设定了“跑赢大盘”的评级。雷蒙德·詹姆斯在9月14日(周三)的一份报告中将89Bio的目标价从14.00美元上调至25.00美元，并给予该公司“强力买入”评级。最后，坎托·菲茨杰拉德在11月14日(周一)的一份报告中重新发布了对89Bio的“增持”评级，并对89Bio的股票发布了34.00美元的目标价(此前为27.00美元)。七位投资分析师对该股的评级为买入，一位分析师对该股的评级为买入。根据MarketBeat的数据，该公司目前的共识评级为买入，共识目标价为25.25美元。约89Bio
(获取评级)
89BioInc.是一家临床阶段的生物制药公司，专注于治疗肝脏和心脏代谢性疾病的疗法的开发和商业化。它的主要候选产品是pegozafermin，一种用于治疗非酒精性脂肪性肝炎的成纤维细胞生长因子21的糖基化类似物。
另请参阅
- 免费获取股票新闻网站89Bio(ETNB)上的研究报告
- MarketBeat：回顾中的一周01/02-01/06
- 为什么CrowdStrike的股价举步维艰？
- 2023年四只被低估的医疗保健股票
- WWE股票：文斯·麦克马洪想要重返节目
- NVIDIA正在触底，但现在还不能买入
接受89Bio日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对89Bio和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧